Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women
Completed
Bayer
Phase 3
2004-04-01
The objective of the study is to evaluate the effects of Angeliq on BP over a period of 8
weeks in postmenopausal women who may benefit from hormone replacement therapy (HRT) for the
relief of vasomotor symptoms and who have hypertension.
Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms.
Completed
Bayer
Phase 3
2006-05-01
The study evaluates in Chinese post-menopausal women the combination of drospirenone 2 mg and
estradiol 1 mg for the treatment of climacteric symptoms, such as hot flushes (vasomotor
symptoms) and uro-genital complaints.
Efficacy and Safety Study of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292002)(P05722)
Completed
Merck Sharp & Dohme Corp.
Phase 3
2006-06-01
The primary purpose of this study is to assess contraceptive efficacy, vaginal bleeding
patterns (cycle control), general safety and acceptability of the nomegestrol
acetate-estradiol (NOMAC-E2) combined oral contraceptive (COC) in a large group of women aged
18-50 years.
Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension
Completed
Bayer
Phase 2
2007-01-01
The main purpose of this study is to compare the effects of treatment of two different
formulations of Angeliq® and Prempro on blood pressure in post-menopausal women with
prehypertension.
Low-dose Hormone Therapy for Relief of Vasomotor Symptoms
Completed
Bayer
Phase 3
2007-03-01
The purpose of this study is to determine the lowest effective dose of the study drug for the
relief of moderate to severe vasomotor symptoms in postmenopausal women for 12 weeks.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
